Unsustainable strain on Europe’s meds supply from geopolitical pressures, Teva says

Israeli generics major Teva Pharmaceutical Industries (NYSE: TEVA) has highlighted that Europe is experiencing increasing pressure on its medicines supply.

From oncology medicines to antibiotics, shortages persist as manufacturers withdraw from the market—in some cases not to be replaced—notes the company’s senior vice president, head of generics Europe and global head for OTC, in a stark warning he issued during a speech at the Medicines for Europe Annual Conference.

Mr Nitka said that securing a reliable supply of essential medicines must be part of Europe’s broader response to a more volatile global environment, with fragile supply chains, trade pressures and rising geopolitical uncertainty putting long-term access to care at risk.